hVIVO Achieves Milestone with Positive RSV Antiviral Trial Results

An announcement from Open Orphan Plc ( (GB:HVO) ) is now available.

hVIVO plc announced Shionogi & Co., Ltd.’s positive results from a Phase 2a Respiratory Syncytial Virus (RSV) human challenge trial conducted by hVIVO, showcasing a significant reduction in viral load for Shionogi’s investigational RSV antiviral candidate, S-337395. This trial underscores the importance of human challenge trials in accelerating drug development, with S-337395 showing an 88.94% reduction in viral load and improved clinical symptoms without significant adverse effects. hVIVO’s expertise in human challenge trials continues to support the advancement of antiviral research, further enhancing its industry-leading position.

More about Open Orphan Plc

hVIVO plc is a rapidly growing early-stage Contract Research Organisation (CRO) and the global leader in human challenge trials. The company provides comprehensive clinical development services to a diverse client base, including major biopharma companies. Specializing in human challenge trials for infectious and respiratory diseases, hVIVO operates a state-of-the-art quarantine facility in London and offers virology and immunology laboratory services. Its subsidiaries in Germany and the UK extend its capabilities in early-phase clinical trials and drug development consulting.

YTD Price Performance: -8.05%

Average Trading Volume: 3,689,165

Technical Sentiment Consensus Rating: Hold

Current Market Cap: £130M

For an in-depth examination of HVO stock, go to TipRanks’ Stock Analysis page.